Power of Attorney Requirements for the Russian Authorized Representative of a Foreign Manufacturer
Updated: 2026-11-12 · GRZAN Regulatory Team · Verification date 2026-10-20
1. Key takeaways
The power of attorney (dovennost, or PoA) that a foreign manufacturer issues to its Russian authorized representative must satisfy at least three requirements. It must expressly authorize the circulation of that manufacturer’s medical devices in the territory of the Russian Federation. It must cover the necessary scope of agency powers: submitting applications on behalf of the manufacturer, signing documents, and receiving correspondence from the regulator. And it must be accompanied by a notarized Russian translation. If any one of these elements is missing, the deficiency will be raised at the dossier review stage and the applicant will be asked to correct it, which costs time and can push the project past internal milestones.
The PoA is not a formality appended to the dossier; it is the legal instrument that makes every subsequent regulatory act of the representative valid. Vigilance submissions, change filings and responses to regulator queries all flow from the powers granted in this document. Drafting it narrowly to save negotiating effort typically produces the opposite result: rework, notarization cycles repeated, and questions from the reviewer about whether the representative had the authority to act at a particular moment in the procedure.
2. Legal basis
The requirements for confirming the powers of the authorized representative are anchored in the national registration rules and related federal acts. The table below lists the instruments relied on in this article, with reference numbers, dates and the specific provisions concerned.
| Legal act | Reference | Date | Provisions |
|---|---|---|---|
| Government Resolution of the Russian Federation on the National Rules for the State Registration of Medical Devices | Government Resolution No. 1684 | 30 November 2024 | paras. 7 and 29 (documents confirming the powers of the representative) |
| Government Resolution of the Russian Federation amending Resolution No. 1684 | Government Resolution No. 1206 | 13 August 2025 (in force from 5 November 2025) | amendments to paras. 7 and 29 |
| Order of the Ministry of Health on the procedure for safety monitoring of medical devices | Order of the Ministry of Health of Russia No. 540n | 26 May 2026 (in force from 1 September 2026) | paras. 5 and 6 (capacity of the representative in monitoring) |
| Federal Law on the Fundamentals of Protection of the Health of Citizens in the Russian Federation | Federal Law No. 323-FZ | 21 November 2011 | Article 38 |
3. Expert insights
Insight one: the PoA must work in three scenarios at once. Under Order No. 540n, the representative must submit preliminary information within 10 working days and complete information within 30 working days. If the power of attorney covers only the submission of the registration application, the company will find itself without a duly empowered agent in the later monitoring phase, precisely when deadlines are short and the consequences of inaction are regulatory. A well-drafted PoA therefore spans registration, vigilance and dossier changes in a single instrument, with powers phrased broadly enough to cover the forms the regulator actually issues.
Insight two: do not draft the PoA as an exclusive authorization. Commercial agency arrangements are better expressed in a confirmation letter format, with a separate distribution agreement signed alongside. An exclusive authorization embedded in the regulatory PoA invites local antitrust compliance attention and can complicate the later addition of a second representative or a second importer. Keeping the regulatory mandate and the commercial relationship in separate documents preserves flexibility on both sides and keeps the dossier clean.
Insight three: the notarization and legalization chain must be complete. In practice the document usually passes through notarization in the manufacturer’s home country, then legalization (an apostille or consular legalization, depending on whether the apostille regime applies locally), and finally notarization of the Russian translation. A break anywhere in this chain is one of the most frequent causes of correction requests. Manufacturers should map the chain before the document is signed, because some steps must be performed in a fixed order and some consulates have long waiting lists.
Insight four: the translation deserves the same rigor as the original. Differences between the Russian translation and the source text, such as a mistranscribed company name, registration number or signatory title, create inconsistencies that the reviewer will flag even when the original document is impeccable. Working with a translator who regularly handles regulatory documents, and proofreading the translation against the original before notarization, prevents a second notarization cycle.
4. Practical recommendations
The following measures reduce the risk that the PoA becomes the bottleneck of the registration timetable. They are drawn from the three mandatory elements summarized above and from the procedural deadlines that the representative must meet after appointment.
- Draft the PoA template around the three mandatory elements and keep the wording open-ended so that additional product lines can be covered without a new instrument for every certificate.
- Align the validity period of the PoA with the CMC documentation and the dossier update dates, so that no mismatch of terms arises between the documents in the file.
- Keep notarized scans of the executed PoA and of the translation in a central archive with a tracking ledger recording issue dates, expiry dates and the authorities in each link of the chain.
- Before signing, confirm with the receiving notary which legalization step the document requires, so the sequence of notarization, apostille or consular legalization and translation is scheduled correctly.
- Review the PoA whenever the representative’s signatory changes, and execute a replacement instrument before the old signatory loses authority.
5. Verification checklist
Use the items below to confirm that the PoA file is complete before it is submitted with the dossier. Each item corresponds to a requirement or risk discussed above.
- □ The authorization clause expressly covers circulation of the devices in the territory of the Russian Federation
- □ The PoA covers the powers to submit documents, sign and receive regulator correspondence
- □ The notarization and notarized Russian translation chain is complete
- □ The document is not drafted as an exclusive authorization or exclusive distribution
- □ The validity of the PoA covers the full cycle of registration, monitoring and changes
Regulatory information verified as of 29 October 2026.
GRZAN assists foreign manufacturers with the full PoA cycle for the Russian market: drafting compliant powers of attorney, coordinating apostille or consular legalization and notarized Russian translations, and acting as the local authorized representative for registration, monitoring and change filings. For support with the appointment package, contact GRZAN at info@grzanglobal.com.
Disclaimer
Prepared by GRZAN from publicly available regulation. It is provided for general information only and does not constitute legal advice. Legislation and official fees are subject to change by the competent authority.
About GRZAN
GRZAN (Global Regulatory Zone Access Navigator) — the global market-access navigator for medical devices and IVDs.
GRZAN is a specialist consultancy for medical device and IVD market access, providing end-to-end regulatory solutions across the product lifecycle and making international market entry simpler and faster.
Key figures. More than 25 wholly owned subsidiaries worldwide covering 50+ countries and regions; chosen by 100+ listed and leading Chinese device manufacturers, with 4,000+ successful cases; 12+ years in the sector and 200+ regulatory training sessions and seminars delivered.
What we do. Global market access: multi-country registration programmes, technical documentation, regulatory advice. Clinical evidence: clinical evaluation reports (CER), usability studies, overseas clinical investigations. Quality systems: ISO 13485, MDSAP, FDA QMSR and BGMP implementation and audit readiness. Authorised representative and licence-holder services across Southeast Asia, Latin America, the Middle East, Africa, Europe and North America.
Why GRZAN. A real operating entity, with the certificate held by the manufacturer: our direct overseas subsidiaries act as the compliant local holder, so the regulatory relationship stays clear and you keep control rather than being tied to a distributor. Direct access to the team: no time-zone gap, no language barrier, no cultural gap. Review points anticipated: we know what FDA 510(k), EU MDR, Southeast Asian, Latin American and Middle Eastern reviewers look for, which shortens timelines and reduces deficiency letters. Pathway planning: pre-decision analysis and risk assessment before you commit.
Every engagement rests on three commitments: efficiency through pre-submission review, certainty through a clear pathway, and stability through a licence-holder that stays in place.
Take your devices global with GRZAN
We work with manufacturers worldwide to open new markets with a clear regulatory pathway.
Contact us